The global male infertility diagnosis and treatment market is anticipated to grow at a considerable CAGR of 4% during the forecast period. The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launches, and product innovation to remain competitive in the marketplace. For instance, Aytu BioScience, Inc. announced the availability of MiOXSYS in the United Kingdom in May 2019. It's the company's seminal oxidative stress test for determining male infertility. One of the leading reasons for male infertility is oxidative stress, which has a deleterious impact on spermatozoa. It is one of the most common causes of sperm failure and DNA damage. MiOXSYS is a cutting-edge in vitro diagnostic test for seminal oxidative stress. It serves as a key indicator of sperm function. This test will allow UK doctors to examine and monitor male infertility patients more effectively.
Browse the full report description of "Global Male Infertility Diagnosis and Treatment Market Size, Share & Trends Analysis Report By Diagnostic Tests (Semen Analysis, Urinalysis, Genetic Testing, Testicular Biopsy, Hormonal Tests, and Others) By Treatment (Drugs, ART Therapy, and Surgery) Forecast Period (2022-2028)"at https://www.omrglobal.com/industry-reports/male-infertility-diagnosis-and-treatment-market
Similarly, in August 2019, Dadi, a Brooklyn-based firm that provides at-home male fertility tests and sperm preservation kits, raised $5 million in venture funding. The organization will be able to use this fresh money to expand its customer support capabilities. In addition, the company will actively focus on the creation of new technology for male infertility now that cash is available. Further, Vitrolife AB acquired Parallabs Ltd., its distributor for EmbryoScope time-lapse equipment in Ireland and the UK, in May 2019. By gaining access to Parallabs' depth of experience, Vitrolife will be able to strengthen its position in Ireland and the UK. It will allow clients to purchase the whole Vitrolife range through a single sales channel. Such advances and financing possibilities are expected to improve the accuracy and reliability of male infertility diagnostic tests, as well as provide a significant opportunity for the global male infertility diagnosis and treatment market to flourish.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- Merck KGaA, Halotech DNA SL, PerkinElmer, Inc., Vitrolife AB, and Medical Electronic Systems. among others.
Key questions addressed by the report
oDeviation from the pre-COVID-19 forecast
oMost affected region and segment
Global Male Infertility Diagnosis and Treatment Market Report Segment
By Diagnostic Test
By Treatment
Global Male Infertility Diagnosis and Treatment Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/industry-reports/male-infertility-diagnosis-and-treatment-market